PE20070076A1 - Aminopirimidinas como moduladores de quinasas - Google Patents

Aminopirimidinas como moduladores de quinasas

Info

Publication number
PE20070076A1
PE20070076A1 PE2006000625A PE2006000625A PE20070076A1 PE 20070076 A1 PE20070076 A1 PE 20070076A1 PE 2006000625 A PE2006000625 A PE 2006000625A PE 2006000625 A PE2006000625 A PE 2006000625A PE 20070076 A1 PE20070076 A1 PE 20070076A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
pyrimidin
piperidin
ester
Prior art date
Application number
PE2006000625A
Other languages
English (en)
Inventor
Michael David Gaul
Guozhang Xu
Christian Andrew Baumann
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20070076A1 publication Critical patent/PE20070076A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE q ES 0, 1 O 2; p ES 0 O 1; Q ES NH, N(ALQUILO), O, O UN ENLACE DIRECTO; Z ES NH, N(ALQUILO), CH2; B ES FENILO, HETEROARILO, O UN HETEROARILO BENZO-FUSIONADO DE UNO A NUEVE MIEMBROS; R1 ES -(CH2)n-Ra; n ES 1, 2, 3 O 4; Ra ES H, ALCOXI, FENOXI, FENILO, ENTRE OTROS; R3 ES H, ALQUILO, ALCOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1- 6-AMINO-5-(METOXIIMINO-METIL)-PIRIMIDIN-4-IL -PIPERIDIN-4-IL ESTER DEL ACIDO (4-ISOPROPOXI-FENIL)-CARBAMICO, 1-{6-AMINO-5-[(2-MORFOLIN-4-IL-ETOXIIMINO)-METIL]-PIRIMIDIN-4-IL}-PIPERIDIN-4-IL ESTER DEL ACIDO (4-ISOPROPOXI-FENIL)-CARBAMICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE PROTEINA TIROSINA QUINASAS, PARTICULARMENTE, INHIBEN LA ACTIVIDAD DE LA QUINASA FLT3 Y/O C-KIT Y/O TrKB Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS CELULARES TALES COMO CANCER, ENTRE OTROS
PE2006000625A 2005-06-10 2006-06-07 Aminopirimidinas como moduladores de quinasas PE20070076A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
PE20070076A1 true PE20070076A1 (es) 2007-02-09

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000625A PE20070076A1 (es) 2005-06-10 2006-06-07 Aminopirimidinas como moduladores de quinasas

Country Status (17)

Country Link
US (1) US20060281764A1 (es)
EP (1) EP1896029A1 (es)
JP (1) JP2008543760A (es)
KR (1) KR20080028911A (es)
AR (1) AR053895A1 (es)
AU (1) AU2006258054A1 (es)
BR (1) BRPI0611963A2 (es)
CA (1) CA2611470A1 (es)
EA (1) EA200800015A1 (es)
EC (1) ECSP077991A (es)
GT (1) GT200600248A (es)
IL (1) IL187693A0 (es)
NI (1) NI200700316A (es)
NO (1) NO20080163L (es)
PE (1) PE20070076A1 (es)
TW (1) TW200718693A (es)
WO (1) WO2006135644A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928862A1 (en) * 2005-09-13 2008-06-11 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
JP5325783B2 (ja) 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
WO2008115263A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
US20110275094A1 (en) * 2008-11-06 2011-11-10 Gunawardane Ruwanthi N Phosphorylated fms-related tyrosine kinase 3 biomarker assay
EP2352730A4 (en) * 2008-11-07 2012-04-25 Lundbeck & Co As H BIOLOGICALLY ACTIVE AMIDES
CN107011330B (zh) 2009-09-04 2020-07-03 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
MX2019000884A (es) 2016-07-21 2019-09-04 Biogen Ma Inc Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
EP3519385B1 (en) * 2016-09-27 2020-11-18 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
JP7106564B2 (ja) * 2017-03-16 2022-07-26 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレータとその使用
MA51840A (fr) * 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
EP3853218A4 (en) 2018-09-18 2022-02-16 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES THEREOF
MX2022001874A (es) 2019-08-14 2022-03-11 Crinetics Pharmaceuticals Inc Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253915T1 (de) * 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors

Also Published As

Publication number Publication date
IL187693A0 (en) 2008-08-07
WO2006135644A1 (en) 2006-12-21
GT200600248A (es) 2007-03-14
EA200800015A1 (ru) 2008-06-30
AR053895A1 (es) 2007-05-23
KR20080028911A (ko) 2008-04-02
US20060281764A1 (en) 2006-12-14
EP1896029A1 (en) 2008-03-12
ECSP077991A (es) 2008-01-23
AU2006258054A1 (en) 2006-12-21
NI200700316A (es) 2009-03-03
TW200718693A (en) 2007-05-16
BRPI0611963A2 (pt) 2010-10-13
NO20080163L (no) 2008-03-07
CA2611470A1 (en) 2006-12-21
JP2008543760A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
PE20070076A1 (es) Aminopirimidinas como moduladores de quinasas
PE20060501A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
PE20091955A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
PE20070070A1 (es) Derivados de tienopiridina y tienopirimidina como agentes moduladores de tirosinquinasa
PE20070111A1 (es) Aminopirimidinas como moduladores de quinasas
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20120546A1 (es) Inhibidores del virus de la hepatitis c
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20141702A1 (es) Compuestos de carbamato y preparacion y uso de los mismos
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20061067A1 (es) Derivados de pirimidina
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20090772A1 (es) Derivados de bencimidazol
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
PE20091712A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20110298A1 (es) Derivados de picolinamida como inhibidores de cinasa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed